# Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer

> **NCT06513455** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Harbin Medical University** · enrollment: 132 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Irinotecan liposome（40mg/m2）
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Irinotecan Liposome（60mg/m2）

## Key facts

- **NCT ID:** NCT06513455
- **Lead sponsor:** Harbin Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06513455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06513455, "Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06513455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*